<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657407</url>
  </required_header>
  <id_info>
    <org_study_id>MMC 2015-63</org_study_id>
    <nct_id>NCT03657407</nct_id>
  </id_info>
  <brief_title>B&amp;O for TLH Post-operative Pain and Nausea</brief_title>
  <official_title>Belladonna and Opium Rectal Suppository Effect on Postoperative Pain and Nausea Following Total Laparoscopic and Robotic-Assisted Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Reinert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mercy Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-center, double-blind, randomized, placebo-controlled trial to assess
      the impact of immediate post-operative placement of a Belladonna and Opium (B&amp;O) rectal
      suppository on postoperative pain and nausea following laparoscopic and robot-assisted
      hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center, double-blind, randomized placebo-controlled trial to assess
      the impact of immediate postoperative Belladonna and Opium rectal suppository use on
      postoperative pain and nausea following total laparoscopic and robot-assisted hysterectomy.
      Study took place at Mercy Medical Center, involving both outpatient and inpatient surgical
      settings. The duration of the trial was 12 months, with 56 patients enrolled during this time
      period. Patients eligible for trial participation were women between ages 18 and 75
      undergoing level I total laparoscopic or robot-assisted hysterectomy with or without
      bilateral salpingo-oophorectomy, with or without cystoscopy performed post-procedure, with or
      without lysis of adhesions, and with or without surgical treatment of endometriosis, with no
      additional surgical procedures being performed (i.e. no lymph node dissection or
      urogynecologic suspension or sling procedures). Patients were excluded from the study if they
      had contraindications to the use of B&amp;O suppositories: these contraindications are glaucoma,
      severe hepatic or renal disease, bronchial asthma, history of narcotic idiosyncracies,
      respiratory depression, convulsive disorders, acute alcoholism or delirium tremens, or
      regular use of an anticholinergic medication (twice per week or more frequently). Patients
      were withdrawn from the study if the original planned surgery was not performed. If the
      original planned surgery was not performed, a suppository was not placed following surgery.
      There were no financial incentives offered for trial participation.

      Only the patients of clinical investigators from this trial were considered for participation
      in this study. Clinical investigators posting patients for total laparoscopic or robotic
      hysterectomy at Mercy Medical Center informed patients of the presence of the clinical trial
      at the time of surgical posting, using an IRB-approved script. The chart number of patients
      posted for total laparoscopic or robot-assisted hysterectomy was be forwarded to the
      co-investigator by the clinic surgical coordinator at the time of surgical posting. The
      co-investigator reviewed each chart and conducted a telephone interview with each patient
      prior to surgery to verify trial eligibility and to answer any questions about the trial.
      Patients were made aware that study participation is voluntary, and that if they chose to not
      participate, they would receive standard postoperative pain and nausea pharmacologic
      management. On the day of surgery, a member of the research team met with the patient
      pre-operatively in a private pre-operative holding area to review and sign a written consent
      for participation in the trial. This member of the research team was familiar with the study
      protocol and risks of the pharmacologic intervention under investigation. These steps allowed
      patients to be fully informed, and ensured patient safety and support during the short
      interval of the study.

      On the day of surgery, patients were randomized to either B&amp;O rectal suppository or to a
      placebo of glycerin rectal suppository. This study employed a glycerin rectal suppository as
      a placebo because this over-the-counter medication has limited effects, similar to those of a
      Belladonna &amp; Opium Supprette, and is similar in size, physical appearance and mechanical
      properties to a Belladonna &amp; Opium Supprette. A placebo-free comparison group was not used,
      as this would have changed the study design from a double-blind clinical trial to a
      single-blind clinical trial, with greater potential for investigator bias to influence study
      results. Additionally, it is not thought that results for a placebo-free comparison group
      would substantially differ from those of a glycerin suppository placebo group, and would
      require a larger study population and greater study resources to achieve findings of similar
      significance and power. Randomization was performed by a biostatistician, with a sealed
      envelope created for each patient containing information regarding randomization to either
      placebo or intervention group. In the operating room, this envelope was opened, and the
      circulating nurse would draw the indicated medication from the Pyxis system. Drug dictionary
      entries were created within the Pyxis system by the Mercy Medical Center Department of
      Pharmacy, so that the Belladonna &amp; Opium Supprette #16A (16.2mg / 60mg), and the glycerin
      suppository were represented as &quot;Protocol Drug A&quot; and &quot;Protocol Drug B&quot;. The patient's
      electronic medical record reflected that &quot;Protocol Drug A&quot; or &quot;Protocol Drug B&quot; was received
      by the patient, so that the nurses and physicians caring for the patient postoperatively were
      blinded as to which suppository the patient received.

      A suppository was placed rectally by a member of the surgical team at the conclusion of
      surgery, prior to departure from the OR and awakening from anesthesia. Post-operative
      placement was selected to minimize interaction with intraoperative anesthetic and analgesic
      medications, to maximize peak plasma concentrations and therapeutic efficacy of Belladonna
      alkaloids and Opium within the immediate postoperative period, and control for variation in
      procedure length between study participants. The nurses caring for the patient
      postoperatively were blinded to which suppository the patient did receive, but were made
      aware that the patient had received a suppository containing either glycerin or one
      containing belladonna 16.2mg and opium 60mg, equivalent to approximately 6mg of morphine. The
      nurses were be educated about potential side effects of Belladonna &amp; Opium suppositories, and
      of potential drug interactions; they were asked to document and to inform the covering
      provider of the occurrence of any such adverse effects. Patients remaining in the hospital
      overnight following their surgery underwent a postoperative exam by a resident physician
      familiar with the study protocol and familiar with potential side effects of the B&amp;O
      suppository. Standard of care at Mercy Medical Center is for nurses to assess patient's
      postoperative pain by visual analog scale at regular time intervals. Data regarding patients'
      visual analog pain scores for the first 12 hours following surgery were extracted from the
      electronic medical record and analyzed by the research team. PO and IV narcotic use in IV
      morphine equivalents, PO and IV NSAIDs, and PO and IV antiemetic use were also assessed over
      the first 12 following surgery, this data was extracted from the electronic medical record
      and analyzed by the research team. Study surveillance did not extend beyond the duration of
      the participant's postoperative hospitalization, usually less than 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to one-time intervention A (medicated suppository) or intervention B (placebo), allocation was sealed in consecutively numbered opaque envelopes generated by biostatistician using blocked randomized technique.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Opaque sealed envelopes generated by biostatistician used to determine intervention A or B. Drug dictionary entries created within the Pyxis system by the Mercy Medical Center Department of Pharmacy, as &quot;Protocol Drug A&quot; and &quot;Protocol Drug B&quot;, recorded in medical record in this way. Identity of &quot;Protocol Drug A&quot; and &quot;Protocol Drug B&quot; revealed by pharmacist at conclusion of data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Pain: VAS</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Visual analog pain scale (VAS) (0 to 10, 0 = no pain, 10 = maximum pain), averaged over duration of PACU stay until discharge criteria met</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic Use</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Cumulative oral and intravenous narcotics received in PACU until PACU discharge criteria met</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Until Cleared for PACU Discharge</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Time elapsed from conclusion of surgery until criteria for PACU discharge met</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants for Which Anti-emetics Were Received in PACU</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Binary assessment of whether anti-emetics received in PACU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hysterectomy</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>B&amp;O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>29 women randomized to Belladonna &amp; Opium suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>27 women randomized to Glycerin suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belladonna Opium</intervention_name>
    <description>Belladonna Opium 16.2-60mg rectal suppository</description>
    <arm_group_label>B&amp;O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin Suppository</intervention_name>
    <description>Glycerine rectal suppository</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between ages 18 and 75,

          -  undergoing level I total laparoscopic or robot-assisted hysterectomy with or without
             bilateral salpingo-oophorectomy, cystoscopy, lysis of adhesions, or surgical treatment
             of endometriosis

        Exclusion Criteria:

          -  contraindications to the use of B&amp;O (i.e. glaucoma, severe hepatic or renal disease,
             bronchial asthma, history of narcotic idiosyncracies, respiratory depression,
             convulsive disorders, acute alcoholism or delirium tremens, or regular use of an
             anticholinergic medication (twice per week or more frequently)

          -  additional surgical procedures being performed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Audlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surgeon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <results_first_submitted>September 6, 2018</results_first_submitted>
  <results_first_submitted_qc>March 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Medical Center</investigator_affiliation>
    <investigator_full_name>Anna Reinert</investigator_full_name>
    <investigator_title>Study coordinator, Resident Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03657407/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A cohort of 281 women was assessed for trial eligibility. Patients were excluded from enrollment if the patient could not be reached pre-operatively (n=47), if inclusion criteria were not met (n=67), or if participation was declined (n=106). A cohort of 61 women met criteria for trial enrollment.</recruitment_details>
      <pre_assignment_details>From a cohort of 61 women meeting criteria for trial enrollment, individuals were excluded from study participation and randomization if the study protocol was not executed by the surgical team i.e. study medication was not ordered/administrated (n=5). 56 women underwent randomization/assignment to the study interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Belladonna &amp; Opium</title>
          <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belladonna &amp; Opium</title>
          <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="7.9"/>
                    <measurement group_id="B2" value="41.8" spread="6.2"/>
                    <measurement group_id="B3" value="43.1" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain-related indication for surgery</title>
          <description>Pre-operative diagnosis of pelvic pain, dysmenorrhea, or dyspareunia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Robotic surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Laparoscopic surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performed by a high-volume surgeon</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery length</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.7" spread="49.7"/>
                    <measurement group_id="B2" value="96.0" spread="49.5"/>
                    <measurement group_id="B3" value="96.9" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned admission for 23-hour observation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dexamethasone while under anesthesia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lidocaine while under anesthesia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ketorolac while under anesthesia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Zofran while under anesthesia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reglan while under anesthesia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scopolamine patch pre-operatively</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Pain: VAS</title>
        <description>Visual analog pain scale (VAS) (0 to 10, 0 = no pain, 10 = maximum pain), averaged over duration of PACU stay until discharge criteria met</description>
        <time_frame>up to 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belladonna &amp; Opium</title>
            <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain: VAS</title>
          <description>Visual analog pain scale (VAS) (0 to 10, 0 = no pain, 10 = maximum pain), averaged over duration of PACU stay until discharge criteria met</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.9"/>
                    <measurement group_id="O2" value="4.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis that Belladonna &amp; Opium not superior to Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Use</title>
        <description>Cumulative oral and intravenous narcotics received in PACU until PACU discharge criteria met</description>
        <time_frame>up to 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belladonna &amp; Opium</title>
            <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Use</title>
          <description>Cumulative oral and intravenous narcotics received in PACU until PACU discharge criteria met</description>
          <units>Oral Morphine Equivalents in mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="14.2"/>
                    <measurement group_id="O2" value="21.3" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis that Belladonna &amp; Opium not superior to Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Until Cleared for PACU Discharge</title>
        <description>Time elapsed from conclusion of surgery until criteria for PACU discharge met</description>
        <time_frame>up to 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belladonna &amp; Opium</title>
            <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until Cleared for PACU Discharge</title>
          <description>Time elapsed from conclusion of surgery until criteria for PACU discharge met</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" spread="36.7"/>
                    <measurement group_id="O2" value="110.6" spread="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis that Belladonna &amp; Opium not superior to Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-19.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants for Which Anti-emetics Were Received in PACU</title>
        <description>Binary assessment of whether anti-emetics received in PACU</description>
        <time_frame>up to 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belladonna &amp; Opium</title>
            <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for Which Anti-emetics Were Received in PACU</title>
          <description>Binary assessment of whether anti-emetics received in PACU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis that Belladonna &amp; Opium not superior to Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of PACU stay (up to 4 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Belladonna &amp; Opium</title>
          <description>29 women randomized to Belladonna &amp; Opium suppository
Belladonna Opium: Belladonna Opium 16.2-60mg rectal suppository</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>27 women randomized to Glycerin suppository
Glycerin Suppository: Glycerine rectal suppository</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was limited by low power; sample size at 50% of target by power calculations.
Pre-operative scopolamine patch use was not controlled within study randomization, and varied significantly between groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anna Reinert, MD</name_or_title>
      <organization>University of Maryland Medical Center</organization>
      <phone>6029089960</phone>
      <email>anna.reinert@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

